Abstract:AbstractFrontotemporal lobar degeneration (FTLD) has been associated with toxic intracellular aggregates of hyperphosphorylated tau (FTLD‐tau). Moreover, genetic studies identified mutations in the MAPT gene encoding tau in familial cases of the disease. In this review, we cover a range of aspects of tau function, both in the healthy and diseased brain, discussing several in vitro and in vivo models. Tau structure and function in the healthy brain is presented, accentuating its distinct compartmentalization in neurons and its role in microtubule stabilization and axonal transport. Furthermore, tau‐driven pathology is discussed, introducing current concepts and the underlying experimental evidence. Different aspects of pathological tau phosphorylation, the protein's genomic and domain organization as well as its spreading in disease, together with MAPT‐associated mutations and their respective models are presented. Dysfunction related to other post‐transcriptional modifications and their effect on normal neuronal functions such as cell cycle, epigenetics and synapse dynamics are also discussed, providing a mechanistic explanation for the observations made in FTLD‐tau cases, with the possibility for therapeutic intervention. image In this review, we cover aspects of tau function, both in the healthy and diseased brain, referring to different in vitro and in vivo models. In healthy neurons, tau is compartmentalized, with higher concentrations found in the distal part of the axon. Cargo molecules are sensitive to this gradient. A disturbed tau distribution, as found in frontotemporal lobar degeneration (FTLD‐tau), has severe consequences for cellular physiology: tau accumulates in the neuronal soma and dendrites, leading among others to microtubule depolymerization and impaired axonal transport. Tau forms insoluble aggregates that sequester additional molecules stalling cellular physiology. Neuronal communication is gradually lost as toxic tau accumulates in dendritic spines with subsequent degeneration of synapses and synaptic loss. Thus, by providing a mechanistic explanation for the observations made in FTLD‐tau cases, arises a possibility for therapeutic interventions.This article is part of the Frontotemporal Dementia special issue.

Tau Toxicity in Neurodegeneration

Tau in neurodegenerative disease

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Tau in Health and Neurodegenerative Diseases

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.

Tauopathies: Mechanisms and Therapeutic Strategies

Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review

Tau in physiology and pathology

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer's Disease

Tauopathies: new perspectives and challenges

Friend or foe: role of pathological tau in neuronal death

Cellular and pathological functions of tau

Influence of Tau on Neurotoxicity and Cerebral Vasculature Impairment Associated with Alzheimer's Disease

Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease

Tau Clearance Mechanisms

Tau physiology and pathomechanisms in frontotemporal lobar degeneration

Abnormal phosphorylation of protein tyrosine in neurodegenerative diseases